Dennis Mccarty

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1923352/publications.pdf

Version: 2024-02-01

57758 106344 5,871 168 44 65 citations h-index g-index papers 173 173 173 4570 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Frequency and recency of non-medical opioid use and death due to overdose or suicide among individuals assessed for risky substance use: A national registry study in Sweden. Journal of Substance Abuse Treatment, 2022, 134, 108567.	2.8	6
2	Effectiveness of and Access to Medications for Opioid Use Disorder for Adolescents and Young Adults: A Scoping Review. Journal of Addiction Medicine, 2022, 16, e157-e164.	2.6	3
3	Recommendations to Inform Substance Use Disorder Data Sharing Research: Scoping Review and Thematic Analysis. Journal of Addiction Medicine, 2022, 16, 261-271.	2.6	2
4	Opioid Treatment Programs, Telemedicine and COVID-19: A Scoping Review. Substance Abuse, 2022, 43, 539-546.	2.3	30
5	HIV clinicâ€based extendedâ€release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a nonâ€blinded, randomized nonâ€inferiority trial. Addiction, 2022, 117, 1961-1971.	3.3	10
6	State policy uptake does not require formal action: A comment on Nesoff <i>et al</i> Addiction, 2022, 117, 2359-2360.	3.3	3
7	Recurrent risk of hospitalization among older people with problematic alcohol use: a multiple failureâ€time analysis with a discontinuous risk model. Addiction, 2022, 117, 2415-2430.	3.3	4
8	Hospital Admission Rate, Cumulative Hospitalized Days, and Time to Admission Among Older Persons With Substance Use and Psychiatric Conditions. Frontiers in Psychiatry, 2022, 13, 882542.	2.6	2
9	Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis. Journal of Substance Abuse Treatment, 2022, 141, 108801.	2.8	26
10	Development and implementation of a prescription opioid registry across diverse health systems. JAMIA Open, 2022, 5, .	2.0	4
11	Differences in the Delivery of Medications for Opioid use Disorder during Hospitalization by Racial Categories: A Retrospective Cohort Analysis;. Substance Abuse, 2022, 43, 1251-1259.	2.3	5
12	Hospital policies for opioid use disorder treatment: A policy content analysis and environmental scan checklist. General Hospital Psychiatry, 2021, 70, 18-24.	2.4	7
13	Interim methadone – Effective but underutilized: A scoping review. Drug and Alcohol Dependence, 2021, 225, 108766.	3.2	4
14	Office-Based Methadone Treatment for Opioid Use Disorder and Pharmacy Dispensing: A Scoping Review. American Journal of Psychiatry, 2021, 178, 804-817.	7.2	16
15	Introduction to a Special Issue: Care and treatment for substance use disorders: Studies from around the world. Journal of Substance Abuse Treatment, 2021, , 108620.	2.8	0
16	Mobile methadone medication units: A brief history, scoping review and research opportunity. Journal of Substance Abuse Treatment, 2021, 129, 108483.	2.8	20
17	Article Commentary: Research Priorities for Expanding access to Methadone Treatment for Opioid use Disorder in the United States: A National Institute on Drug Abuse Clinical Trials Network Task Force Report. Substance Abuse, 2021, 42, 245-254.	2.3	22
18	Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis. Addiction Science & Eamp; Clinical Practice, 2021, 16, 67.	2.6	3

#	Article	IF	Citations
19	Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis. Addiction Science & Elinical Practice, 2021, 16, 72.	2.6	26
20	"Now hospital leaders are paying attention†A qualitative study of internal and external factors influencing addiction consult services. Journal of Substance Abuse Treatment, 2020, 110, 59-65.	2.8	32
21	Expanding Access to Medications for Opioid Use Disorder: Program and Policy Approaches from Outside the Veterans Health Administration. Journal of General Internal Medicine, 2020, 35, 886-890.	2.6	11
22	Substance Use Disorders and COVID-19: Multi-Faceted Problems Which Require Multi-Pronged Solutions. Frontiers in Psychiatry, 2020, 11, 714.	2.6	84
23	Opioid Agonist Therapy During Hospitalization Within the Veterans Health Administration: a Pragmatic Retrospective Cohort Analysis. Journal of General Internal Medicine, 2020, 35, 2365-2374.	2.6	43
24	The National Drug Abuse Treatment Clinical Trials Network: From 2000 to 2020 and beyond. Journal of Substance Abuse Treatment, 2020, 112, 1-3.	2.8	3
25	Medicaid expansion and treatment for opioid use disorders in Oregon: an interrupted time-series analysis. Addiction Science & Emp; Clinical Practice, 2019, 14, 31.	2.6	16
26	Interpretation and integration of the federal substance use privacy protection rule in integrated health systems: A qualitative analysis. Journal of Substance Abuse Treatment, 2019, 97, 41-46.	2.8	22
27	A Changing Landscape for Treatment of Alcohol and Drug Use Disorders. American Journal of Public Health, 2019, 109, 838-839.	2.7	2
28	The payer's role in addressing the opioid epidemic: It's more than money. Journal of Substance Abuse Treatment, 2019, 101, 72-78.	2.8	8
29	Predictors of Substance use Treatment Initiation and Engagement among Adult and Adolescent Medicaid Recipients. Substance Abuse, 2019, 40, 285-291.	2.3	10
30	Measurementâ€based care: the implementation challenge. Addiction, 2019, 114, 1354-1355.	3.3	2
31	Barriers to Buprenorphine Expansion in Ohio: A Time-Elapsed Qualitative Study. Journal of Psychoactive Drugs, 2019, 51, 272-279.	1.7	21
32	Comparing Canadian and United States opioid agonist therapy policies. International Journal of Drug Policy, 2019, 74, 257-265.	3.3	50
33	Role of the Hospital in the 21st Century Opioid Overdose Epidemic: The Addiction Medicine Consult Service. Journal of Addiction Medicine, 2019, 13, 104-112.	2.6	78
34	Opioid use disorder and treatment: challenges and opportunities. BMC Health Services Research, 2019, 19, 884.	2.2	42
35	Making the business case for an addiction medicine consult service: a qualitative analysis. BMC Health Services Research, 2019, 19, 822.	2.2	14
36	Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial. BMC Health Services Research, 2019, 19, 862.	2.2	26

#	Article	IF	Citations
37	Use of single IRBs for multi-site studies: A case report and commentary from a National Drug Abuse Treatment Clinical Trials Network study. Contemporary Clinical Trials Communications, 2019, 14, 100319.	1.1	12
38	Overcoming Barriers to Adopting and Implementing Pharmacotherapy: the Medication Research Partnership. Journal of Behavioral Health Services and Research, 2019, 46, 330-339.	1.4	6
39	Public Health Policy Strategies to Address the Opioid Epidemic. Clinical Pharmacology and Therapeutics, 2018, 103, 959-962.	4.7	8
40	Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities. Annual Review of Public Health, 2018, 39, 525-541.	17.4	57
41	Does Medical Cannabis Reduce Use of Prescription Opioids?. American Journal of Psychiatry, 2018, 175, 6-7.	7.2	6
42	Barriers and facilitators affecting the implementation of substance use screening in primary care clinics: a qualitative study of patients, providers, and staff. Addiction Science & Dinical Practice, 2018, 13, 8.	2.6	162
43	Quality Metrics and Systems Transformation: Are We Advancing Alcohol and Drug Screening in Primary Care?. Health Services Research, 2018, 53, 1702-1726.	2.0	8
44	Association of Prescription Drug Monitoring Program Use With Opioid Prescribing and Health Outcomes: A Comparison of Program Users and Nonusers. Journal of Pain, 2018, 19, 166-177.	1.4	52
45	Payer Policy Behavior Towards Opioid Pharmacotherapy Treatment in Ohio. Journal of Addiction Medicine, 2018, 12, 85-91.	2.6	4
46	Access to treatment for alcohol use disorders following Oregon's health care reforms and Medicaid expansion. Journal of Substance Abuse Treatment, 2018, 94, 24-28.	2.8	8
47	An Item Bank for Abuse of Prescription Pain Medication from the Patient-Reported Outcomes Measurement Information System (PROMIS [®]). Pain Medicine, 2017, 18, pnw233.	1.9	13
48	Feasibility and safety of extendedâ€release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Addiction, 2017, 112, 1036-1044.	3.3	51
49	Early Performance in Medicaid Accountable Care Organizations. JAMA Internal Medicine, 2017, 177, 538.	5.1	55
50	Patient-reported pathways to opioid use disorders and pain-related barriers to treatment engagement. Journal of Substance Abuse Treatment, 2017, 73, 47-54.	2.8	88
51	Primary Care–Based Models for the Treatment of Opioid Use Disorder. Annals of Internal Medicine, 2017, 166, 268.	3.9	224
52	Toward a Patient Registry for Cannabis Use: An Exploratory Study of Patient Use in an Outpatient Health are Clinic in Oregon. World Medical and Health Policy, 2017, 9, 307-317.	1.6	4
53	The Perceived Impact of 42 CFR Part 2 on Coordination and Integration of Care: A Qualitative Analysis. Psychiatric Services, 2017, 68, 245-249.	2.0	26
54	Promoting Adoption of Medication for Opioid and Alcohol Use Disorders Through System Change. Journal of Studies on Alcohol and Drugs, 2017, 78, 735-744.	1.0	13

#	Article	IF	Citations
55	Management of Suspected Opioid Overdose With Naloxone in Out-of-Hospital Settings. Annals of Internal Medicine, 2017, 167, 867.	3.9	51
56	Frequency of Cannabis Use Among Primary Care Patients in Washington State. Journal of the American Board of Family Medicine, 2017, 30, 795-805.	1.5	33
57	Disparities in Alcohol, Drug Use, and Mental Health Condition Prevalence and Access to Care in Rural, Isolated, and Reservation Areas: Findings From the South Dakota Health Survey. Journal of Rural Health, 2016, 32, 287-302.	2.9	29
58	The Concentration of Opioid Prescriptions by Providers and Among Patients in the Oregon Medicaid Program. Psychiatric Services, 2016, 67, 397-404.	2.0	23
59	Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use. Journal of Substance Abuse Treatment, 2016, 62, 68-73.	2.8	52
60	Understanding opioid overdose characteristics involving prescription and illicit opioids: A mixed methods analysis. Drug and Alcohol Dependence, 2016, 167, 49-56.	3.2	43
61	Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. Drug and Alcohol Dependence, 2016, 160, 112-118.	3.2	121
62	A Qualitative Analysis of Family Involvement in Prescribed Opioid Medication Monitoring among Individuals who Have Experienced Opioid Overdoses. Substance Abuse, 2016, 37, 96-103.	2.3	12
63	The relationship of therapeutic alliance and treatment delivery fidelity with treatment retention in a multisite trial of twelve-step facilitation Psychology of Addictive Behaviors, 2015, 29, 106-113.	2.1	16
64	Item banks for substance use from the Patient-Reported Outcomes Measurement Information System (PROMIS \hat{A}^{\otimes}): Severity of use and positive appeal of use. Drug and Alcohol Dependence, 2015, 156, 184-192.	3.2	35
65	A Longitudinal Study of State Strategies and Policies to Accelerate Evidenceâ€Based Practices in the Context of Systems Transformation. Health Services Research, 2015, 50, 1125-1145.	2.0	22
66	What Influences Participation in QI? A Randomized Trial of Addiction Treatment Organizations. Journal for Healthcare Quality: Official Publication of the National Association for Healthcare Quality, 2015, 37, 342-353.	0.7	4
67	Oregon's strategy to confront prescription opioid misuse: a case study. Journal of Substance Abuse Treatment, 2015, 48, 91-95.	2.8	14
68	Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio. Substance Abuse Treatment, Prevention, and Policy, 2015, 10, 13.	2.2	42
69	Substance Abuse Intensive Outpatient Programs: Assessing the Evidence. Psychiatric Services, 2014, 65, 718-726.	2.0	51
70	A qualitative study of the adoption of buprenorphine for opioid addiction treatment. Journal of Substance Abuse Treatment, 2014, 46, 390-401.	2.8	47
71	Extended-release naltrexone for alcohol and opioid dependence: A meta-analysis of healthcare utilization studies. Journal of Substance Abuse Treatment, 2014, 47, 113-121.	2.8	49
72	Costs of care for persons with opioid dependence in commercial integrated health systems. Addiction Science & Clinical Practice, 2014, 9, 16.	2.6	33

#	Article	IF	CITATIONS
73	Does treatment fidelity predict client outcomes in 12-Step Facilitation for stimulant abuse?. Drug and Alcohol Dependence, 2014, 134, 330-336.	3.2	19
74	Oregon's Medicaid transformation: An innovative approach to holding a health system accountable for spending growth. Healthcare, 2014, 2, 163-167.	1.3	43
75	Testing use of payers to facilitate evidence-based practice adoption: protocol for a cluster-randomized trial. Implementation Science, 2013, 8, 50.	6.9	6
76	Therapist predictors of treatment delivery fidelity in a community-based trial of 12-step facilitation. American Journal of Drug and Alcohol Abuse, 2013, 39, 304-311.	2.1	37
77	Possible barriers to enrollment in substance abuse treatment among a diverse sample of Asian Americans and Pacific Islanders: Opinions of treatment clients. Journal of Substance Abuse Treatment, 2013, 44, 309-315.	2.8	41
78	Clinician attitudes, social norms and intentions to use a computer-assisted intervention. Journal of Substance Abuse Treatment, 2013, 44, 433-437.	2.8	18
79	Item banks for alcohol use from the Patient-Reported Outcomes Measurement Information System (PROMIS®): Use, consequences, and expectancies. Drug and Alcohol Dependence, 2013, 130, 167-177.	3.2	54
80	A Highâ€Resolution Analysis of Process Improvement: Use of Quantile Regression for Wait Time. Health Services Research, 2013, 48, 333-347.	2.0	9
81	HIV infection among people who inject drugs: The challenge of racial/ethnic disparities American Psychologist, 2013, 68, 274-285.	4.2	14
82	Measures Such As Interstate Cooperation Would Improve The Efficacy Of Programs To Track Controlled Drug Prescriptions. Health Affairs, 2013, 32, 603-613.	5.2	40
83	Which elements of improvement collaboratives are most effective? A clusterâ€randomized trial. Addiction, 2013, 108, 1145-1157.	3.3	104
84	Improving the Quality of Addiction Treatment. , 2013, , 579-588.		4
85	Development of a Multilevel Framework to Increase Use of Targeted Evidence-Based Practices in Addiction Treatment Clinics. Public Health Frontier, 2013, 2, 11-20.	0.1	7
86	American Indians with Substance Use Disorders: Treatment Needs and Comorbid Conditions. American Journal of Drug and Alcohol Abuse, 2012, 38, 498-504.	2.1	44
87	Behavioral Health Insurance Parity: Does Oregon's Experience Presage the National Experience With the Mental Health Parity and Addiction Equity Act?. American Journal of Psychiatry, 2012, 169, 31-38.	7.2	43
88	Advancing Recovery: Implementing Evidence-Based Treatment for Substance Use Disorders at the Systems Level. Journal of Studies on Alcohol and Drugs, 2012, 73, 413-422.	1.0	28
89	A multilevel approach to predicting community addiction treatment attitudes about contingency management. Journal of Substance Abuse Treatment, 2012, 42, 213-221.	2.8	24
90	Treatment length and outcomes among adolescents: a secondary data analysis. Substance Abuse Treatment, Prevention, and Policy, 2012, 7, 35.	2,2	2

#	Article	IF	Citations
91	Improving Quality of Care in Substance Abuse Treatment Using Five key Process Improvement Principles. Journal of Behavioral Health Services and Research, 2012, 39, 234-244.	1.4	35
92	A Business Case for Quality Improvement in Addiction Treatment: Evidence from the NIATx Collaborative. Journal of Behavioral Health Services and Research, 2012, 39, 91-100.	1.4	14
93	Days to treatment and early retention among patients in treatment for alcohol and drug disorders. Addictive Behaviors, 2011, 36, 643-647.	3.0	56
94	Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, S83-S90.	2.1	45
95	Community-based addiction treatment staff attitudes about the usefulness of evidence-based addiction treatment and CBO organizational linkages to research institutions. Evaluation and Program Planning, 2011, 34, 356-365.	1.6	22
96	Employing policy and purchasing levers to increase the use of evidence-based practices in community-based substance abuse treatment settings: Reports from single state authorities. Evaluation and Program Planning, 2011, 34, 366-374.	1.6	27
97	Reducing HIV-Related Risk Behaviors Among Injection Drug Users in Residential Detoxification. AIDS and Behavior, 2011, 15, 30-44.	2.7	39
98	Substance Use and the Quality of Patient-Provider Communication in HIV Clinics. AIDS and Behavior, 2011, 15, 832-841.	2.7	36
99	Disseminating quality improvement: study protocol for a large cluster-randomized trial. Implementation Science, 2011, 6, 44.	6.9	22
100	Improving substance abuse data systems to measure †waiting time to treatment': Lessons learned from a quality improvement initiative. Health Informatics Journal, 2011, 17, 256-265.	2.1	10
101	The Substance Abuse Counseling Workforce: Education, Preparation, and Certification. Substance Abuse, 2011, 32, 180-190.	2.3	13
102	Patients' Reasons for Choosing Office-Based Buprenorphine: Preference for Patient-Centered Care. Journal of Addiction Medicine, 2010, 4, 204-210.	2.6	56
103	Adoption of practice guidelines and assessment tools in substance abuse treatment. Substance Abuse Treatment, Prevention, and Policy, 2010, 5, 4.	2.2	3
104	The Use of Health Information Technology in Publicly-Funded U. S. Substance Abuse Treatment Agencies. Contemporary Drug Problems, 2010, 37, 315-339.	1.6	6
105	Predicting outpatient treatment entry following detoxification for injection drug use: The impact of patient and program factors. Journal of Substance Abuse Treatment, 2010, 38, 587-596.	2.8	23
106	From research to the real world: Buprenorphine in the decade of the Clinical Trials Network. Journal of Substance Abuse Treatment, 2010, 38, S53-S60.	2.8	45
107	The first decade of the National Drug Abuse Treatment Clinical Trials Network: Bridging the gap between research and practice to improve drug abuse treatment. Journal of Substance Abuse Treatment, 2010, 38, S4-S13.	2.8	65
108	Priorities for policy research on treatments for alcohol and drug use disorders. Journal of Substance Abuse Treatment, 2010, 39, 87-95.	2.8	21

#	Article	IF	Citations
109	Substance abuse treatment providers' involvement in research is associated with willingness to use findings in practice. Journal of Substance Abuse Treatment, 2010, 39, 188-194.	2.8	29
110	Methadone maintenance and the cost and utilization of health care among individuals dependent on opioids in a commercial health plan. Drug and Alcohol Dependence, 2010, 111, 235-240.	3.2	36
111	Health Services Research for Drug and Alcohol Treatment and Prevention. Journal of Drug Issues, 2009, 39, 197-208.	1.2	5
112	Improving Care for the Treatment of Alcohol and Drug Disorders. Journal of Behavioral Health Services and Research, 2009, 36, 52-60.	1.4	52
113	Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine–naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. Drug and Alcohol Dependence, 2009, 99, 28-36.	3.2	59
114	Understanding the importance of organizational and system variables on addiction treatment services within criminal justice settings. Drug and Alcohol Dependence, 2009, 103, S91-S93.	3.2	21
115	Management practices in substance abuse treatment programs. Journal of Substance Abuse Treatment, 2009, 37, 79-89.	2.8	35
116	Medicaid Coverage, Methadone Maintenance, and Felony Arrests: Outcomes of Opiate Treatment in Two States. Journal of Addictive Diseases, 2009, 28, 89-102.	1.3	39
117	Understanding attitudes toward use of medication in substance abuse treatment: A multilevel approach Psychological Services, 2009, 6, 74-84.	1.5	30
118	Facilitating outpatient treatment entry following detoxification for injection drug use: A multisite test of three interventions Psychology of Addictive Behaviors, 2009, 23, 260-270.	2.1	28
119	Implementation of MET/CBT 5 for Adolescents. Journal of Behavioral Health Services and Research, 2008, 35, 304-314.	1.4	18
120	Treatment programs in the National Drug Abuse Treatment Clinical Trials Network. Drug and Alcohol Dependence, 2008, 92, 200-207.	3.2	46
121	Replication and sustainability of improved access and retention within the Network for the Improvement of Addiction Treatment. Drug and Alcohol Dependence, 2008, 98, 63-69.	3.2	78
122	Crossing the Quality Chasm: Challenges for Counselor Training Programs. Journal of Teaching in the Addictions, 2008, 6, 1-7.	0.3	1
123	Making "Stone Soup― Improvements in Clinic Access and Retention in Addiction Treatment. Joint Commission Journal on Quality and Patient Safety, 2007, 33, 95-103.	0.7	62
124	Direct Care Workers in the National Drug Abuse Treatment Clinical Trials Network: Characteristics, Opinions, and Beliefs. Psychiatric Services, 2007, 58, 181-190.	2.0	73
125	The Network for the Improvement of Addiction Treatment (NIATx): Enhancing access and retention. Drug and Alcohol Dependence, 2007, 88, 138-145.	3.2	186
126	Attitudes toward the integration of smoking cessation treatment into drug abuse clinics. Journal of Substance Abuse Treatment, 2007, 32, 53-60.	2.8	107

#	Article	IF	Citations
127	Client and counselor attitudes toward the use of medications for treatment of opioid dependence. Journal of Substance Abuse Treatment, 2007, 32, 207-215.	2.8	71
128	Organizational Readiness for Change and opinions toward treatment innovations. Journal of Substance Abuse Treatment, 2007, 33, 183-192.	2.8	104
129	Performance measurement for systems treating alcohol and drug use disorders. Journal of Substance Abuse Treatment, 2007, 33, 353-354.	2.8	12
130	Direct Care Workers in the National Drug Abuse Treatment Clinical Trials Network: Characteristics, Opinions, and Beliefs. Psychiatric Services, 2007, 58, 181-190.	2.0	78
131	Addiction Treatment Agencies' Use of Data: A Qualitative Assessment. Journal of Behavioral Health Services and Research, 2006, 33, 394-407.	1.4	41
132	Buprenorphine and HIV Primary Care: Report of a Forum for Collaborative HIV Research Workshop. Clinical Infectious Diseases, 2006, 43, S254-S257.	5.8	19
133	Charting a path between research and practice in alcoholism treatment. Alcohol Research, 2006, 29, 5-10.	1.0	7
134	Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. , $2005, 108, 119-128.$		49
135	Adoption of naltrexone to treat alcohol dependence. Journal of Substance Abuse Treatment, 2005, 28, 273-280.	2.8	56
136	Stakeholders in Recovery: Demands, Expectations, and Research Opportunities. Science & Practice Perspectives / A Publication of the National Institute on Drug Abuse, National Institutes of Health, 2005, 3, 34-37.	0.4	2
137	Bringing Buprenorphine-Naloxone Detoxification to Community Treatment Providers: The NIDA Clinical Trials Network Field Experience. American Journal on Addictions, 2004, 13, S42-S66.	1.4	130
138	Self-help organizations for alcohol and drug problems: Toward evidence-based practice and policy. Journal of Substance Abuse Treatment, 2004, 26, 151-158.	2.8	206
139	Training rural practitioners to use buprenorphine. Journal of Substance Abuse Treatment, 2004, 26, 203-208.	2.8	47
140	State substance abuse and mental health managed care evaluation program. Journal of Behavioral Health Services and Research, 2003, 30, 7-17.	1.4	17
141	The Iowa Managed Substance Abuse Care Plan: Access, utilization, and expenditures for medicaid recipients. Journal of Behavioral Health Services and Research, 2003, 30, 18-25.	1.4	18
142	How did the introduction of managed care for the uninsured in Iowa affect the use of substance abuse services?. Journal of Behavioral Health Services and Research, 2003, 30, 26-40.	1.4	18
143	Research to practice. Journal of Substance Abuse Treatment, 2003, 24, 1-11.	2.8	140
144	Performance measures for outpatient substance abuse services: Group versus individual counseling. Journal of Substance Abuse Treatment, 2003, 25, 271-278.	2.8	26

#	Article	IF	CITATIONS
145	Research to practice: adoption of naltrexone in alcoholism treatment. Journal of Substance Abuse Treatment, 2003, 24, 1-11.	2.8	66
146	Effects of Managed Care on Programs and Practices for the Treatment of Alcohol and Drug Dependence., 2002, 15, 51-71.		23
147	The Severity Index. Alcoholism Treatment Quarterly, 2001, 19, 49-64.	0.8	10
148	Introduction. Journal of Behavioral Health Services and Research, 2001, 28, 115-117.	1.4	1
149	Public sector managed care for substance abuse treatment: Opportunities for health services research. Journal of Behavioral Health Services and Research, 2001, 28, 143-154.	1.4	12
150	The Impact of Substance Abuse Treatment Modality on Birth Weight and Health Care Expenditures. Journal of Psychoactive Drugs, 2001, 33, 57-66.	1.7	22
151	Between despair and hope: health services research on treatment of alcohol abuse. Addiction, 2000, 95, 439-447.	3.3	5
152	Welfare Reform and the Changing Landscape of Substance Abuse Services for Low-Income Women. Alcoholism: Clinical and Experimental Research, 2000, 24, 1298-1311.	2.4	42
153	Detoxification centers: Who's in the revolving door?. Journal of Behavioral Health Services and Research, 2000, 27, 245-256.	1.4	31
154	Between despair and hope: health services research on treatment of alcohol abuse. Addiction, 2000, 95, 439-447.	3.3	4
155	The costs of crime and the benefits of substance abuse treatment for pregnant women. Journal of Substance Abuse Treatment, 2000, 19, 445-458.	2.8	41
156	Methadone Maintenance and State Medicaid Managed Care Programs. Milbank Quarterly, 1999, 77, 341-362.	4.4	35
157	Substance abuse treatment for pregnant women: a window of opportunity?. Addictive Behaviors, 1998, 23, 239-249.	3.0	75
158	Using State Information Systems for Drug Abuse Services Research. American Behavioral Scientist, 1998, 41, 1090-1106.	3.8	52
159	Substance abuse treatment and HIV services: Massachusetts' policies and programs. Journal of Substance Abuse Treatment, 1996, 13, 429-438.	2.8	10
160	Use of the addiction severity index with homeless substance abusers. Journal of Substance Abuse Treatment, 1994, 11, 359-365.	2.8	57
161	Substance abuse treatment management information systems: Balancing federal, state, and service provider needs. Journal of Mental Health Administration, 1992, 19, 5-20.	1.1	29
162	Alcoholism, drug abuse, and the homeless American Psychologist, 1991, 46, 1139-1148.	4.2	56

DENNIS MCCARTY

#	Article	IF	CITATION
163	Nine Demonstration Grants:. Alcoholism Treatment Quarterly, 1990, 7, 1-9.	0.8	9
164	Reasons for drinking: Motivational patterns and alcohol use among college students. Addictive Behaviors, 1984, 9, 185-188.	3.0	45
165	A residence hall tavern as a collegiate alcohol abuse prevention activity. Addictive Behaviors, 1983, 8, 105-108.	3.0	6
166	Alcohol, sexual arousal, and the transfer of excitation Journal of Personality and Social Psychology, 1982, 42, 977-988.	2.8	12
167	Changing Contraceptive Usage Intentions: A Test of the Fishbein Model of Intention1. Journal of Applied Social Psychology, 1981, 11, 192-211.	2.0	54
168	Guidelines for Alcohol Abuse Prevention on the College Campus: Overcoming the Barriers to Program Success. Journal of Higher Education, 1981, 52, 399.	2.7	14